FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:1679-1680 April 15, 2004 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Gene therapy has endured several setbacks in recent years. One setback involved infants born with X-linked severe combined immunodeficiency (SCID) resulting from a mutation of the c gene who were successfully treated with an infusion of autologous hematopoietic stem cells transduced with a defective retroviral vector.¹ The enthusiasm generated by the apparent cure of 9 of the 10 infants turned to alarm when, nearly three years after treatment, T-cell leukemia developed in 2 of the boys.² A recent study by Davé and colleagues,³ however, suggests that this setback may have been due to a coincidence and that it is possible . . . [Full Text of this Article]

Source Information

From the Division of Molecular Genetics, the Netherlands Cancer Institute, Amsterdam.

This article has been cited by other articles:

• Cappelen, A W, Norheim, O F, Tungodden, B (2008). Genomics and equal opportunity ethics. J. Med. Ethics 34: 361-364 [Abstract] [Full Text]  
• Cornetta, K., Pollok, K. E., Miller, A. D. (2008). Retroviral Vectors for Gene Transfer. CSH Protocols 2008: pdb.top29-pdb.top29 [Abstract] [Full Text]